TurkmenistanTuberculosis profile
Population  2016 5.7 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.43 (0.38–0.48) 7.6 (6.7–8.5)
Mortality (HIV+TB only) 0.037 (0.016–0.066) 0.65 (0.28–1.2)
Incidence  (includes HIV+TB) 3.4 (2.6–4.3) 60 (46–76)
Incidence (HIV+TB only) 0.18 (0.084–0.31) 3.2 (1.5–5.5)
Incidence (MDR/RR-TB)** 0.83 (0.65–1) 15 (11–18)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.19 (0.14–0.24) 0.98 (0.73–1.2) 1.2 (0.88–1.5)
Males 0.2 (0.15–0.25) 2 (1.5–2.6) 2.2 (1.7–2.8)
Total 0.39 (0.29–0.49) 3 (2.3–3.8) 3.4 (2.6–4.3)
TB case notifications, 2016  
Total cases notified 2 376
Total new and relapse 2 104
          - % tested with rapid diagnostics at time of diagnosis 77%
          - % with known HIV status  
          - % pulmonary 77%
          - % bacteriologically confirmed among pulmonary 100%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 62% (49–81)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.14 (0.1–0.18)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  360
(300–420)
Estimated % of TB cases with MDR/RR-TB 14% (11–17) 38% (28–49)  
% notified tested for rifampicin resistance 77% 56% 1 736
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 557, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 557, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 86% 2 472
Previously treated cases, excluding relapse, registered in 2015 80% 281
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014 53% 81
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 1.8
Funding source:  domestic, 100% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data